-
Je něco špatně v tomto záznamu ?
The NBN founder mutation-Evidence for a country specific difference in age at cancer manifestation
KH. Chrzanowska, E. Seemanova, R. Varon, M. Digweed, D. Piekutowska-Abramczuk, K. Sperling, P. Seeman
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Directory of Open Access Journals
od 2021
PubMed Central
od 2018
ProQuest Central
od 2020-08-01
Health & Medicine (ProQuest)
od 2020-08-01
Wiley Free Content
od 2018
Wiley-Blackwell Open Access Titles
od 2021
ROAD: Directory of Open Access Scholarly Resources
od 2018
PubMed
36806726
DOI
10.1002/cnr2.1700
Knihovny.cz E-zdroje
- MeSH
- heterozygot MeSH
- jaderné proteiny genetika MeSH
- lidé MeSH
- mutace MeSH
- nádory * MeSH
- proteiny buněčného cyklu genetika MeSH
- syndrom Nijmegen breakage * genetika patologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: Nijmegen breakage syndrome (NBS) is an autosomal-recessive chromosome instability disorder characterized by, among others, hypersensitivity to X-irradiation and an exceptionally high risk for lymphoid malignancy. The vast majority of NBS patients is homozygous for a common Slavic founder mutation, c.657del5, of the NBN gene, which is involved in the repair of DNA double-strand breaks (DSBs). The founder mutation also predisposes heterozygous carriers to cancer, apparently however, with a higher risk in the Czech Republic/Slovakia (CS) than in Poland. AIM: To examine whether the age of cancer manifestation and cancer death of NBN homozygotes is different between probands from CS and Poland. METHODS: The study is restricted to probands born until 1989, before replacement of the communist regime by a democratic system in CS and Poland, and a substantial transition of the health care systems. Moreover, all patients were recruited without knowledge of their genetic status since the NBN gene was not identified until 1998. RESULTS: Here, we show that cancer manifestation of NBN homozygotes is at a significantly earlier age in probands from CS than from Poland. This is explained by the difference in natural and medical radiation exposure, though within the permissible dosage. CONCLUSION: It is reasonable to assume that this finding also sheds light on the higher cancer risk of NBN heterozygotes in CS than in Poland. This has implications for genetic counseling and individualized medicine also of probands with other DNA repair defects.
Department of Medical Genetics The Children's Memorial Health Institute Warsaw Poland
Institute of Medical and Human Genetics Charité Universitätsmedizin Berlin Berlin Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23004275
- 003
- CZ-PrNML
- 005
- 20230425141244.0
- 007
- ta
- 008
- 230418s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/cnr2.1700 $2 doi
- 035 __
- $a (PubMed)36806726
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Chrzanowska, Krystyna H $u Department of Medical Genetics, The Children's Memorial Health Institute, Warsaw, Poland
- 245 14
- $a The NBN founder mutation-Evidence for a country specific difference in age at cancer manifestation / $c KH. Chrzanowska, E. Seemanova, R. Varon, M. Digweed, D. Piekutowska-Abramczuk, K. Sperling, P. Seeman
- 520 9_
- $a BACKGROUND: Nijmegen breakage syndrome (NBS) is an autosomal-recessive chromosome instability disorder characterized by, among others, hypersensitivity to X-irradiation and an exceptionally high risk for lymphoid malignancy. The vast majority of NBS patients is homozygous for a common Slavic founder mutation, c.657del5, of the NBN gene, which is involved in the repair of DNA double-strand breaks (DSBs). The founder mutation also predisposes heterozygous carriers to cancer, apparently however, with a higher risk in the Czech Republic/Slovakia (CS) than in Poland. AIM: To examine whether the age of cancer manifestation and cancer death of NBN homozygotes is different between probands from CS and Poland. METHODS: The study is restricted to probands born until 1989, before replacement of the communist regime by a democratic system in CS and Poland, and a substantial transition of the health care systems. Moreover, all patients were recruited without knowledge of their genetic status since the NBN gene was not identified until 1998. RESULTS: Here, we show that cancer manifestation of NBN homozygotes is at a significantly earlier age in probands from CS than from Poland. This is explained by the difference in natural and medical radiation exposure, though within the permissible dosage. CONCLUSION: It is reasonable to assume that this finding also sheds light on the higher cancer risk of NBN heterozygotes in CS than in Poland. This has implications for genetic counseling and individualized medicine also of probands with other DNA repair defects.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a jaderné proteiny $x genetika $7 D009687
- 650 _2
- $a proteiny buněčného cyklu $x genetika $7 D018797
- 650 12
- $a nádory $7 D009369
- 650 _2
- $a heterozygot $7 D006579
- 650 12
- $a syndrom Nijmegen breakage $x genetika $x patologie $7 D049932
- 650 _2
- $a mutace $7 D009154
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Seemanova, Eva $u Department of Clinical Genetics, Institute of Biology and Medical Genetics, 2nd Medical School, Charles University, Prague, Czech Republic
- 700 1_
- $a Varon, Raymonda $u Institute of Medical and Human Genetics, Charité-Universitätsmedizin Berlin, Berlin, Germany
- 700 1_
- $a Digweed, Martin $u Institute of Medical and Human Genetics, Charité-Universitätsmedizin Berlin, Berlin, Germany
- 700 1_
- $a Piekutowska-Abramczuk, Dorota $u Department of Medical Genetics, The Children's Memorial Health Institute, Warsaw, Poland
- 700 1_
- $a Sperling, Karl $u Institute of Medical and Human Genetics, Charité-Universitätsmedizin Berlin, Berlin, Germany $1 https://orcid.org/0000000323054370
- 700 1_
- $a Seeman, Pavel $u DNA Laboratory, Department of Pediatric Neurology, 2nd Medical School, Charles University, University Hospital Motol, Prague, Czech Republic
- 773 0_
- $w MED00209152 $t Cancer reports (Hoboken, N.J.) $x 2573-8348 $g Roč. 6, č. 2 (2023), s. e1700
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36806726 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425141241 $b ABA008
- 999 __
- $a ok $b bmc $g 1924756 $s 1190484
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 6 $c 2 $d e1700 $e 20220810 $i 2573-8348 $m Cancer reports $n Cancer Rep (Hoboken) $x MED00209152
- LZP __
- $a Pubmed-20230418